CoChat

Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial

Open access

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index; 18 of the 27 sources its claims cite were checked for support.

Abstract

People with type 2 diabetes and chronic kidney disease have a high risk for kidney failure and cardiovascular (CV) complications. Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors (SGLT2i) independently reduce CV and kidney events. The effect of combining both is unclear. FLOW trial participants with type 2 diabetes and chronic kidney disease were stratified by baseline SGLT2i use ( N = 550) or no use ( N = 2,983) and randomized to semaglutide/placebo. The primary outcome was a composite of kidney failure, ≥50% estimated glomerular filtration rate reduction, kidney death or CV death. The risk of the primary outcome was 24% lower in all participants treated with semaglutide versus placebo (95% confidence interval: 34%, 12%). The primary outcome occurred in 41/277 (semaglutide) versus 38/273 (placebo) participants on SGLT2i at baseline (hazard ratio 1.07; 95% confidence interval: 0.69, 1.67; P = 0.755) and in 290/1,490 versus 372/1,493 participants not taking SGLT2i at baseline (hazard ratio 0.73; 0.63, 0.85; P < 0.001; P interaction 0.109). Three confirmatory secondary outcomes were predefined. Treatment differences favoring semaglutide for total estimated glomerular filtration rate slope (ml min −1 /1.73 m 2 /year) were 0.75 (−0.01, 1.5) in the SGLT2i subgroup and 1.25 (0.91, 1.58) in the non-SGLT2i subgroup, P interaction 0.237. Semaglutide benefits on major CV events and all-cause death were similar regardless of SGLT2i use ( P interaction 0.741 and 0.901, respectively). The benefits of semaglutide in reducing kidney outcomes were consistent in participants with/without baseline SGLT2i use; power was limited to detect smaller but clinically relevant effects. ClinicalTrials.gov identifier: NCT03819153 .

Overview

CoChat Summary

TL;DR

In a prespecified FLOW trial analysis, semaglutide reduced kidney and cardiovascular outcomes in participants with type 2 diabetes and chronic kidney disease, with no clear heterogeneity by baseline SGLT2 inhibitor use. The SGLT2i subgroup was small, so the analysis was underpowered to detect smaller but clinically relevant interactions.

Key findings

  • The primary composite outcome occurred in 41/277 (14.8%) semaglutide vs 38/273 (13.9%) placebo participants on baseline SGLT2i (HR 1.07; 95% CI 0.69, 1.67; P = 0.755), and in 290/1,490 (19.5%) vs 372/1,493 (24.9%) without baseline SGLT2i (HR 0.73; 95% CI 0.63, 0.85; P < 0.001; P interaction 0.109).
  • Treatment differences favoring semaglutide for total eGFR-creatinine slope were 0.75 ml min−1/1.73 m2/year (95% CI −0.01, 1.50) with baseline SGLT2i and 1.25 ml min−1/1.73 m2/year (95% CI 0.91, 1.58) without baseline SGLT2i (P interaction 0.237).
  • Semaglutide benefits on MACE and all-cause death were similar regardless of baseline SGLT2i use (P interaction 0.741 and 0.901, respectively).
  • UACR was lowered by semaglutide vs placebo at week 104 by 24% (95% CI 4%, 39%) with baseline SGLT2i and 34% (95% CI 26%, 40%) without baseline SGLT2i (P interaction 0.279).

Methods

  • Prespecified analysis of the FLOW trial, a randomized, double-blind, placebo-controlled, international, multicenter kidney outcomes trial in participants with type 2 diabetes and chronic kidney disease.
  • 3,533 participants were randomized to semaglutide 1.0 mg once weekly or placebo; randomization was stratified by baseline SGLT2i use: 550 reported baseline SGLT2i use (277 semaglutide, 273 placebo) and 2,983 did not.
  • Time-to-event outcomes used stratified Cox proportional hazards models with treatment and SGLT2i subgroup interaction terms; eGFR slopes used linear random regression, and continuous endpoints used ANCOVA with multiple imputation for missing values.

Limitations

  • The paper states that power was limited because only 15.6% of randomized participants used SGLT2i at baseline, so small but clinically relevant interactions may not have been detected; the study was not designed to test specific subgroups.
  • The paper states that post-baseline SGLT2i initiations were not controlled and more participants initiated SGLT2i in the placebo group.
  • The text makes evident that no adjustment for multiplicity or alpha-protection was performed, and the median follow-up of 3.4 years may be too short to examine kidney outcomes beyond eGFR and UACR in the relatively small baseline SGLT2i cohort.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41591-024-03133-0

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Outcomes for semaglutide 1.0 mg versus placebo in subgroups with/without SGLT2i use at baseline for the primary five-component outcome and for the kidney-specific, four-component outcome. a, For the primary five-component outcome, cumulative incidence rates were calculated using the Aalen–Johansen method with non-CV and non-renal death as a competing risk. b, For the kidney-specific, four-component outcome (five-component outcome without CV death), cumulative incidence rates were calculated using the Aalen–Johansen method with all-cause death, excluding renal death, as a competing risk. A stratified Cox proportional hazards model was used (stratified by SGLT2i use at baseline (yes/no)), with treatment and subgroup as fixed factors and two-sided P values. In a, the P value for semaglutide versus placebo in participants on SGLT2i at baseline was 0.7546, and for those not on SGLT2i, it was <0.0001; the P interaction value was 0.1090.
Fig. 1 Outcomes for semaglutide 1.0 mg versus placebo in subgroups with/without SGLT2i use at baseline for the primary five-component outcome and for the kidney-specific, four-component outcome. a, For the primary five-component outcome, cumulative incidence rates were calculated using the Aalen–Johansen method with non-CV and non-renal death as a competing risk. b, For the kidney-specific, four-component outcome (five-component outcome without CV death), cumulative incidence rates were calculated using the Aalen–Johansen method with all-cause death, excluding renal death, as a competing risk. A stratified Cox proportional hazards model was used (stratified by SGLT2i use at baseline (yes/no)), with treatment and subgroup as fixed factors and two-sided P values. In a, the P value for semaglutide versus placebo in participants on SGLT2i at baseline was 0.7546, and for those not on SGLT2i, it was <0.0001; the P interaction value was 0.1090.CC BY · PubMed Central
Fig. 2 The composite primary outcome and its components, and MACE and all-cause death outcomes. Data from the in-trial period (full analysis set). Data are presented as HR (blue symbol) and corresponding 95% CI (error bars). Time from randomization to relevant endpoint was analyzed using a stratified Cox proportional hazards model with treatment as a categorical fixed factor and two-sided P values. Participants without events of interest were censored at the end of their in-trial period. For the subgroup analyses, estimated HR and corresponding CI were calculated in a Cox proportional hazards model with interaction between treatment groups and subgroup as a fixed factor. P interaction values for the test of no interaction effect between SGLT2i use and treatment using a score test are shown. There was no renal death in the SGLT2i use subgroup, which is not displayed here. MI, myocardial infarction.
Fig. 2 The composite primary outcome and its components, and MACE and all-cause death outcomes. Data from the in-trial period (full analysis set). Data are presented as HR (blue symbol) and corresponding 95% CI (error bars). Time from randomization to relevant endpoint was analyzed using a stratified Cox proportional hazards model with treatment as a categorical fixed factor and two-sided P values. Participants without events of interest were censored at the end of their in-trial period. For the subgroup analyses, estimated HR and corresponding CI were calculated in a Cox proportional hazards model with interaction between treatment groups and subgroup as a fixed factor. P interaction values for the test of no interaction effect between SGLT2i use and treatment using a score test are shown. There was no renal death in the SGLT2i use subgroup, which is not displayed here. MI, myocardial infarction.CC BY · PubMed Central
Fig. 3 eGFR over time with or without SGLT2i use at baseline, based on serum creatinine and cystatin C. a–d, Observed data from the in-trial period. eGFR-creatinine in subgroup with SGLT2i use at baseline (a), eGFR-creatinine in subgroup without SGLT2i use at baseline (b), eGFR-cystatin C in subgroup with SGLT2i use at baseline (c) and eGFR-cystatin C in subgroup without SGLT2i use at baseline (d). Error bars are ± s.e.m. Numbers shown under the plots represent the number of participants contributing to the means. s.e.m., standard error of the mean.
Fig. 3 eGFR over time with or without SGLT2i use at baseline, based on serum creatinine and cystatin C. a–d, Observed data from the in-trial period. eGFR-creatinine in subgroup with SGLT2i use at baseline (a), eGFR-creatinine in subgroup without SGLT2i use at baseline (b), eGFR-cystatin C in subgroup with SGLT2i use at baseline (c) and eGFR-cystatin C in subgroup without SGLT2i use at baseline (d). Error bars are ± s.e.m. Numbers shown under the plots represent the number of participants contributing to the means. s.e.m., standard error of the mean.CC BY · PubMed Central
Extended Data Fig. 1 Participant disposition and flow. *Five participants were randomized more than once, and one participant was excluded due to good clinical practice issues at the site. †Fourteen additional withdrawals (two participants receiving semaglutide and twelve receiving placebo) were by sponsor decision, following closure of two sanctioned sites in Russia. ‡Participants who attended the follow-up visit or died during the trial. FAS, full analysis set; SGLT2i, sodium-glucose co-transporter-2 inhibitors.
Extended Data Fig. 1 Participant disposition and flow. *Five participants were randomized more than once, and one participant was excluded due to good clinical practice issues at the site. †Fourteen additional withdrawals (two participants receiving semaglutide and twelve receiving placebo) were by sponsor decision, following closure of two sanctioned sites in Russia. ‡Participants who attended the follow-up visit or died during the trial. FAS, full analysis set; SGLT2i, sodium-glucose co-transporter-2 inhibitors.CC BY · PubMed Central
Extended Data Fig. 2 Compliance on randomized treatment over time by baseline SGLT2i use (participants planned to be on treatment). The lines represent the proportion of participants compliant on treatment until the planned end-of-treatment visit. Compliance on-treatment period: all days from the date of first dose to the end of the in-trial period where a dose has been administered. The period could include non-consecutive time intervals, and the dose did not have to be the target dose. SGLT2i, sodium-glucose co-transporter-2 inhibitors.
Extended Data Fig. 2 Compliance on randomized treatment over time by baseline SGLT2i use (participants planned to be on treatment). The lines represent the proportion of participants compliant on treatment until the planned end-of-treatment visit. Compliance on-treatment period: all days from the date of first dose to the end of the in-trial period where a dose has been administered. The period could include non-consecutive time intervals, and the dose did not have to be the target dose. SGLT2i, sodium-glucose co-transporter-2 inhibitors.CC BY · PubMed Central
Extended Data Fig. 3 Proportion of participants on SGLT2i at baseline who continued on SGLT2i during the trial. Proportions are based upon the number of participants in the trial at a given time point. SGLT2i, sodium-glucose co-transporter-2 inhibitors.
Extended Data Fig. 3 Proportion of participants on SGLT2i at baseline who continued on SGLT2i during the trial. Proportions are based upon the number of participants in the trial at a given time point. SGLT2i, sodium-glucose co-transporter-2 inhibitors.CC BY · PubMed Central
Extended Data Fig. 4 Proportion of participants not on SGLT2i at baseline who started on SGLT2i during the trial (grey and blue areas). Proportions are based upon the number of participants in the trial at a given time point. The red line indicates open-label use of GLP-1 RA. GLP-1 RA, glucagon-like peptide-1 receptor agonist; SGLT2i, sodium-glucose co-transporter-2 inhibitors.
Extended Data Fig. 4 Proportion of participants not on SGLT2i at baseline who started on SGLT2i during the trial (grey and blue areas). Proportions are based upon the number of participants in the trial at a given time point. The red line indicates open-label use of GLP-1 RA. GLP-1 RA, glucagon-like peptide-1 receptor agonist; SGLT2i, sodium-glucose co-transporter-2 inhibitors.CC BY · PubMed Central
Extended Data Fig. 5 Time to first MACE with semaglutide or placebo according to baseline use of SGLT2i. Cumulative incidence was calculated using the Aalen–Johansen estimator for first MACE accounting for non-CV death as a competing event. CV, cardiovascular; MACE, major adverse CV event (non fatal myocardial infarction, non fatal stroke or CV death); SGLT2i, sodium-glucose co-transporter-2 inhibitors.
Extended Data Fig. 5 Time to first MACE with semaglutide or placebo according to baseline use of SGLT2i. Cumulative incidence was calculated using the Aalen–Johansen estimator for first MACE accounting for non-CV death as a competing event. CV, cardiovascular; MACE, major adverse CV event (non fatal myocardial infarction, non fatal stroke or CV death); SGLT2i, sodium-glucose co-transporter-2 inhibitors.CC BY · PubMed Central
Extended Data Fig. 6 Time to all-cause death with semaglutide or placebo according to baseline use of SGLT2i. Cumulative incidence was calculated using the Aalen–Johansen method for all-cause death. SGLT2i, sodium-glucose co-transporter-2 inhibitors.
Extended Data Fig. 6 Time to all-cause death with semaglutide or placebo according to baseline use of SGLT2i. Cumulative incidence was calculated using the Aalen–Johansen method for all-cause death. SGLT2i, sodium-glucose co-transporter-2 inhibitors.CC BY · PubMed Central
Extended Data Fig. 7 UACR over time in participants with SGLT2i use at baseline (a) or without (b). Observed data from the in-trial period. Error bars are +/– the standard error of the mean on the logarithmic scale back-transformed to natural scale with the exponential. Numbers shown in the lower panel represent the number of participants contributing to the means. SGLT2i, sodium-glucose co-transporter-2 inhibitors; UACR, urine albumin-to-creatinine ratio.
Extended Data Fig. 7 UACR over time in participants with SGLT2i use at baseline (a) or without (b). Observed data from the in-trial period. Error bars are +/– the standard error of the mean on the logarithmic scale back-transformed to natural scale with the exponential. Numbers shown in the lower panel represent the number of participants contributing to the means. SGLT2i, sodium-glucose co-transporter-2 inhibitors; UACR, urine albumin-to-creatinine ratio.CC BY · PubMed Central
Extended Data Fig. 8 Most frequent serious adverse events by baseline SGLT2i use; by system organ class (a) and by preferred term (b). Percentages are sorted in descending order by the frequency in the semaglutide 1.0 mg group. Most frequent was defined as the 10 most frequent terms by absolute count, where absolute count was >1 in the total population (up to 15 in case of a tie). N, number of participants in the semaglutide and placebo arms. COVID-19, coronavirus disease 2019; SGLT2i, sodium-glucose co-transporter-2 inhibitors. Note that the percentage range (abscissa) varies.
Extended Data Fig. 8 Most frequent serious adverse events by baseline SGLT2i use; by system organ class (a) and by preferred term (b). Percentages are sorted in descending order by the frequency in the semaglutide 1.0 mg group. Most frequent was defined as the 10 most frequent terms by absolute count, where absolute count was >1 in the total population (up to 15 in case of a tie). N, number of participants in the semaglutide and placebo arms. COVID-19, coronavirus disease 2019; SGLT2i, sodium-glucose co-transporter-2 inhibitors. Note that the percentage range (abscissa) varies.CC BY · PubMed Central

Verification

Claims the paper makes

13 Valid · 1 Not valid · 4 Not checked · 65 Own results and interpretations

36 more claims · 1 with their cited sources checked

Create a free account to see all 83 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 28
  • Probably not a substantial claim. 15

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 24 references

Research works printed but not linked: 1

  1. Neuen, B. Efficacy and safety of SGLT2 inhibitors with and without GLP-1 receptor agonists: a SMART-C collaborative meta-analysis. Nephrol. Dial. Transpl. 39, e061807 (2024).

Cited by

See all 200

Metadata

Authors
Mann, J. F. E., Rossing, P., Bakris, G., Belmar, N., Bosch-Traberg, H., Busch, R., Charytan, D. M., Hadjadj, S., Gillard, P., Górriz, J. L., Idorn, T., Ji, L., Mahaffey, K. W., Perkovic, V., Rasmussen, S., Schmieder, R. E., Pratley, R. E., & Tuttle, K. R.
Affiliations
  • Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
  • University of Copenhagen (DK)
  • University of Chicago (US)
  • Novo Nordisk (Denmark) (DK)
  • Albany Medical Center Hospital (US)
  • NYU Langone Health (US)
  • Centre National de la Recherche Scientifique (FR)
  • KU Leuven (BE)
  • Universitat de València (ES)
  • Peking University People's Hospital (CN)
  • Stanford Medicine (US)
  • UNSW Sydney (AU)
  • AdventHealth Orlando (US)
  • University of Washington (US)
Corresponding author
Mann, Johannes F. E.
Venue
Nature Medicine
Published
2024-06-24
Volume
30
Issue
10
Pages
2849-2856
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W4399940216
Cited by
200
References
23
Citations by year
2026: 78 · 2025: 87 · 2024: 35
FWCI
65.42
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by)
  • HAL (submittedVersion, cc-by)
  • Lirias (KU Leuven) (submittedVersion, cc-by)
  • Repository of Digital Objects for Teaching Research and Culture (University of Valencia) (submittedVersion, other-oa)
Funders
Novo Nordisk
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
Keywords
semaglutide, SGLT2 inhibitors, type 2 diabetes, chronic kidney disease, GLP-1 receptor agonists, renal failure, estimated glomerular filtration rate decline, cardiovascular events, all-cause mortality, combination therapy, FLOW trial, drug interactions, cardiovascular safety, renal safety, glycemic control, blood pressure
MeSH terms
Sodium-Glucose Transporter 2 Inhibitors, Semaglutide, Aged, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Female, Glomerular Filtration Rate, Humans, Hypoglycemic Agents, Male, Middle Aged, Treatment Outcome, Renal Insufficiency, Chronic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-16, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-16 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial. https://app.cochat.ai/papers/10.1038/s41591-024-03133-0
The paper
Mann, J. F. E., Rossing, P., Bakris, G., Belmar, N., Bosch-Traberg, H., Busch, R., Charytan, D. M., Hadjadj, S., Gillard, P., Górriz, J. L., Idorn, T., Ji, L., Mahaffey, K. W., Perkovic, V., Rasmussen, S., Schmieder, R. E., Pratley, R. E., & Tuttle, K. R. (2024). Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial. Nature Medicine. https://doi.org/10.1038/s41591-024-03133-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.